Homologous recombination (HR) is a highly conserved DNA repair mechanism that protects
cells from exogenous and endogenous DNA damage. Breast cancer 1 (BRCA1) and breast …

Epithelial ovarian cancer (EOC) is one of the deadliest gynaecological malignancies. The
late diagnosis is frequent due to the absence of specific symptomatology and the molecular …

ABSTRACT PARP inhibitors are synthetically lethal with BRCA1/2 mutations, and in this
setting, accumulation of DNA damage leads to cell death. Because increased DNA damage …

Breast cancer and gynecological tumors seriously endanger women's physical and mental
health, fertility, and quality of life. Due to standardized surgical treatment, chemotherapy, and …

Highlights•Preclinical data indicate that PARPis exhibit immune modulating properties.•The
combination of PARPi with ICIs displays significant synergistic activity in preclinical …

Although PARP inhibitor (PARPi) has been proven to be a promising anticancer drug in
cancer patients harboring BRCA1/2 mutation, it provides limited clinical benefit in colorectal …

Nanotechnology has emerged as a promising approach for the targeted delivery of
therapeutic agents while improving their efficacy and safety. As a result, nanomaterial …

Background: Since its discovery, poly (ADP-ribose) polymerase 1 (PARP-1) has been
extensively studied due to its regulatory role in numerous biologically crucial pathways …

The advent of polyadenosine diphosphate ribose polymerase inhibitors (PARPi) has
brought about significant changes in the field of ovarian cancer treatment. However, in 2022 …

Anti-programmed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) antibodies
have developed rapidly but exhibited modest activity in ovarian cancer (OC), achieving a …